用于上气消化道癌症化疗的可植入静脉装置的并发症

F. Hoareau-Gruchet , R. Rtail , H. Sulaj , A. Khirnetkina , E. Reyt , C.A. Righini
{"title":"用于上气消化道癌症化疗的可植入静脉装置的并发症","authors":"F. Hoareau-Gruchet ,&nbsp;R. Rtail ,&nbsp;H. Sulaj ,&nbsp;A. Khirnetkina ,&nbsp;E. Reyt ,&nbsp;C.A. Righini","doi":"10.1016/j.aorl.2009.02.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To review the occurrence of early and delayed complications after insertion of a totally implantable venous access port (Tivap) in patients treated with chemotherapy for head and neck squamous cell carcinoma.</p></div><div><h3>Material and methods</h3><p>Monocentric prospective study (2005–2008) undertaken in a tertiary referral center. In all cases, the inserted Tivap was a Celsite ST301 (Braun<sup>®</sup>) model. The insertion procedure was performed in operating room conditions under local anesthesia using a surgical cut-down method. No antibiotic prophylaxis or long-term anticoagulant medications were administered. Two groups were made between experienced and in-training surgeons. All complications occurring from the date of Tivap insertion to the date of its removal or until the closure of the study were included.</p></div><div><h3>Results</h3><p>The study comprised of 122 patients including 103 males and 19 females; the patients’ mean age was 58.5 years (range, 36–80). Twelve (9.8%) had a tracheotomy or tracheostomy and 41 (33.6%) underwent cervical radiotherapy before Tivap insertion. In 63 cases (51.6%), the procedure was performed by a senior surgeon. The inserted vessel was the cephalic vein (84.4%), the external jugular vein (11.5%) or the internal jugular vein (2.5%). Overall, the total number of days of Tivap implantation was 51,403. Altogether, 11 complications (9%) were listed: two (1.6%) early complications and nine (7.4%) delayed complications. We did not uncover a significant statistical relation between complication onset and experience of the operating surgeon, sex, implanted side, tracheotomy, previous radiotherapy, or number of days of Tivap port.</p></div><div><h3>Conclusion</h3><p>Our study suggests that: (1) complications are rare provided careful implantation and manipulation methods are followed by health personnel; (2) surgical cephalic cut-down is a very reliable method; and 3) antibiotic prophylaxis or long-term anticoagulant medications are not mandatory.</p></div>","PeriodicalId":75509,"journal":{"name":"Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris","volume":"126 2","pages":"Pages 43-52"},"PeriodicalIF":0.0000,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.aorl.2009.02.005","citationCount":"4","resultStr":"{\"title\":\"Complications d’un dispositif intraveineux implantable pour chimiothérapie dans les cancers des voies aérodigestives supérieures\",\"authors\":\"F. Hoareau-Gruchet ,&nbsp;R. Rtail ,&nbsp;H. Sulaj ,&nbsp;A. Khirnetkina ,&nbsp;E. Reyt ,&nbsp;C.A. Righini\",\"doi\":\"10.1016/j.aorl.2009.02.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>To review the occurrence of early and delayed complications after insertion of a totally implantable venous access port (Tivap) in patients treated with chemotherapy for head and neck squamous cell carcinoma.</p></div><div><h3>Material and methods</h3><p>Monocentric prospective study (2005–2008) undertaken in a tertiary referral center. In all cases, the inserted Tivap was a Celsite ST301 (Braun<sup>®</sup>) model. The insertion procedure was performed in operating room conditions under local anesthesia using a surgical cut-down method. No antibiotic prophylaxis or long-term anticoagulant medications were administered. Two groups were made between experienced and in-training surgeons. All complications occurring from the date of Tivap insertion to the date of its removal or until the closure of the study were included.</p></div><div><h3>Results</h3><p>The study comprised of 122 patients including 103 males and 19 females; the patients’ mean age was 58.5 years (range, 36–80). Twelve (9.8%) had a tracheotomy or tracheostomy and 41 (33.6%) underwent cervical radiotherapy before Tivap insertion. In 63 cases (51.6%), the procedure was performed by a senior surgeon. The inserted vessel was the cephalic vein (84.4%), the external jugular vein (11.5%) or the internal jugular vein (2.5%). Overall, the total number of days of Tivap implantation was 51,403. Altogether, 11 complications (9%) were listed: two (1.6%) early complications and nine (7.4%) delayed complications. We did not uncover a significant statistical relation between complication onset and experience of the operating surgeon, sex, implanted side, tracheotomy, previous radiotherapy, or number of days of Tivap port.</p></div><div><h3>Conclusion</h3><p>Our study suggests that: (1) complications are rare provided careful implantation and manipulation methods are followed by health personnel; (2) surgical cephalic cut-down is a very reliable method; and 3) antibiotic prophylaxis or long-term anticoagulant medications are not mandatory.</p></div>\",\"PeriodicalId\":75509,\"journal\":{\"name\":\"Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris\",\"volume\":\"126 2\",\"pages\":\"Pages 43-52\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.aorl.2009.02.005\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0003438X0900019X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003438X0900019X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

摘要

目的探讨全植入式静脉通路(Tivap)在头颈部鳞状细胞癌化疗后早期和延迟并发症的发生情况。材料与方法在某三级转诊中心进行的单中心前瞻性研究(2005-2008)。在所有病例中,插入的Tivap均为Celsite ST301 (Braun®)型号。插入过程是在局部麻醉下的手术室条件下使用手术切下的方法进行的。未给予抗生素预防或长期抗凝药物。两组由经验丰富的外科医生和实习外科医生组成。包括从植入Tivap到取出Tivap或直到研究结束时发生的所有并发症。结果共纳入122例患者,其中男性103例,女性19例;患者平均年龄58.5岁(36-80岁)。12例(9.8%)行气管切开术或气管造口术,41例(33.6%)行颈椎放疗。63例(51.6%)由资深外科医生进行手术。插入血管为头静脉(84.4%)、颈外静脉(11.5%)和颈内静脉(2.5%)。总的来说,Tivap植入的总天数为51,403天。共有11例并发症(9%),其中早期并发症2例(1.6%),迟发性并发症9例(7.4%)。我们没有发现并发症的发生与手术医生的经验、性别、植入侧、气管切开术、既往放疗或Tivap端口天数之间有显著的统计关系。结论:(1)在医护人员的指导下,通过精心的植入和操作方法,术后并发症极少;(2)手术头侧切开是一种非常可靠的方法;3)抗生素预防或长期抗凝药物不是强制性的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Complications d’un dispositif intraveineux implantable pour chimiothérapie dans les cancers des voies aérodigestives supérieures

Objectives

To review the occurrence of early and delayed complications after insertion of a totally implantable venous access port (Tivap) in patients treated with chemotherapy for head and neck squamous cell carcinoma.

Material and methods

Monocentric prospective study (2005–2008) undertaken in a tertiary referral center. In all cases, the inserted Tivap was a Celsite ST301 (Braun®) model. The insertion procedure was performed in operating room conditions under local anesthesia using a surgical cut-down method. No antibiotic prophylaxis or long-term anticoagulant medications were administered. Two groups were made between experienced and in-training surgeons. All complications occurring from the date of Tivap insertion to the date of its removal or until the closure of the study were included.

Results

The study comprised of 122 patients including 103 males and 19 females; the patients’ mean age was 58.5 years (range, 36–80). Twelve (9.8%) had a tracheotomy or tracheostomy and 41 (33.6%) underwent cervical radiotherapy before Tivap insertion. In 63 cases (51.6%), the procedure was performed by a senior surgeon. The inserted vessel was the cephalic vein (84.4%), the external jugular vein (11.5%) or the internal jugular vein (2.5%). Overall, the total number of days of Tivap implantation was 51,403. Altogether, 11 complications (9%) were listed: two (1.6%) early complications and nine (7.4%) delayed complications. We did not uncover a significant statistical relation between complication onset and experience of the operating surgeon, sex, implanted side, tracheotomy, previous radiotherapy, or number of days of Tivap port.

Conclusion

Our study suggests that: (1) complications are rare provided careful implantation and manipulation methods are followed by health personnel; (2) surgical cephalic cut-down is a very reliable method; and 3) antibiotic prophylaxis or long-term anticoagulant medications are not mandatory.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信